Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.48T
24h Vol:
$8.69B
Dominance:
MSFT:4.77%
Stocklytics Platform
Instrument logo  AMLX
Amylyx Pharmaceuticals
AMLX
77 / 100
Penny Stock
$1.98arrow_drop_up5.88%$0.11

Performance History

Stocklytics logo
Key Stats
Open$1.90
Prev. Close$1.87
EPS0.7
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap134208552.00
PE Ratio2.83
LOWHIGH
Day Range1.90
2.02
52 Week Range1.85
31.21
Ratios
P/B Ratio0.31
Revenue-
Operating M. %1.78%
Earnings$49.27M
Earnings Growth %124.84%
EBITDA Margin %10.48%
ROE %12.73%
EPS0.7

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

77vs 54. Market Avg.

All Score 77 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

AMLXMARKET
Value7440
Quality6640
Ownership617
Growth6846
Dividends-37
check_circle

Amylyx Pharmaceuticals's Price discount from 1 year high of 93.46% is great compared to market average of 19.18%. This indicates AMLX could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$726.31
24H (%)arrow_drop_down2.63%
24H ($)-$19.64
MARKET CAP$690.55B
PRICE$501.13
24H (%)arrow_drop_up1.61%
24H ($)$7.95
MARKET CAP$432.28B
PRICE$147.91
24H (%)arrow_drop_up1.48%
24H ($)$2.17
MARKET CAP$356.43B
PRICE$125.78
24H (%)arrow_drop_up0.43%
24H ($)$0.55
MARKET CAP$318.60B

About Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Joshua B. Cohen
Headquarters
Cambridge
Employees
338
Exchange
NASDAQ
add Amylyx Pharmaceuticals to watchlist

Keep an eye on Amylyx Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Amylyx Pharmaceuticals's (AMLX) price per share?

The current price per share for Amylyx Pharmaceuticals (AMLX) is $1.87. The stock has seen a price change of -$0.11 recently, indicating a -5.56% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Amylyx Pharmaceuticals (AMLX)?

For Amylyx Pharmaceuticals (AMLX), the 52-week high is $31.77, which is 1.6K% from the current price. The 52-week low is $1.85, the current price is 1.08% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Amylyx Pharmaceuticals (AMLX) a growth stock?

Amylyx Pharmaceuticals (AMLX) has shown an average price growth of 44.63% over the past three years. It has received a score of 90 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Amylyx Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Amylyx Pharmaceuticals (AMLX) stock price performance year to date (YTD)?

As of the latest data, Amylyx Pharmaceuticals (AMLX) has a year-to-date price change of -87.5%. Over the past month, the stock has experienced a price change of -37.04%. Over the last three months, the change has been -87.28%. Over the past six months, the figure is -88.9%.

help
Is Amylyx Pharmaceuticals (AMLX) a profitable company?

Amylyx Pharmaceuticals (AMLX) has a net income of $49.27M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.32% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 1.78% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $355.34M. Operating income is noted at $38.8M. Furthermore, the EBITDA is $39.89M.

help
What is the market capitalization of Amylyx Pharmaceuticals (AMLX)?

Amylyx Pharmaceuticals (AMLX) has a market capitalization of $127.77M. The average daily trading volume is 2.5M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.